控股股东重组改为定增入主，药用玻璃龙头山东药玻迎新主国药集团

Core Viewpoint - Shandong Pharmaceutical Glass (山东药玻) has terminated its restructuring plan with its controlling shareholder after over a year of planning, but China National Pharmaceutical Group (国药集团) remains interested and will instead invest directly in the company through a private placement. Group 1: Fundraising and Shareholding Structure - The company plans to raise no more than 3.235 billion yuan through a private placement, with the net proceeds intended to supplement working capital [1] - The issuance will involve China International Pharmaceutical Health Co., Ltd. (国药国际) and Shandong Yaoxin Health Industry Co., Ltd. (山东耀新), with the latter being a wholly-owned subsidiary of 国药国际 [2] - After the issuance, 国药国际 and 山东耀新 will collectively hold 199 million shares, representing 23.08% of the total share capital, making 国药国际 the controlling shareholder [2] Group 2: Termination of Previous Restructuring Plan - The termination of the restructuring plan was due to the complexity of the involved parties and changes in the market environment since the initial planning [3] - The decision was made after friendly consultations among the parties involved, and there are no disputes or other agreements related to the investment cooperation [3] Group 3: Company Performance and Market Position - Shandong Pharmaceutical Glass is a leading company in the pharmaceutical glass industry in China, specializing in core processes such as borosilicate molded bottles and borosilicate tubes [3] - The company reported a decline in revenue and net profit for the first three quarters of 2025, with revenue of approximately 3.401 billion yuan, down 11.1% year-on-year, and net profit of about 542 million yuan, down 24.7% year-on-year [5] - The decline in performance is attributed to decreased revenue, increased inventory impairment losses, and rising management expenses [6] Group 4: Strategic Goals and Future Outlook - The fundraising aims to enhance the company's research and innovation capabilities and increase investment in new technologies and products [4] - The collaboration with 国药集团 is expected to help Shandong Pharmaceutical Glass overcome performance and development bottlenecks, while also strengthening the self-sufficiency of the pharmaceutical supply chain in China [6]